HUTCHMED (China) Ltd (NAS:HCM)
$ 21.75 0.93 (4.47%) Market Cap: 3.76 Bil Enterprise Value: 2.96 Bil PE Ratio: 40.46 PB Ratio: 5.21 GF Score: 85/100

HUTCHMED (China) Ltd at Bank of America Global Healthcare Conference Transcript

May 10, 2023 / 10:40PM GMT
Release Date Price: $14.15 (+0.57%)
Alec Warren Stranahan
BofA Securities, Research Division - Associate

Hey, everyone. Good afternoon, and welcome to day 2 of the 2023 BofA Healthcare Conference. Thanks for joining the session with HUTCHMED. My name is Alec Stranahan. I'm Vice President and senior biotech analyst covering HUTCHMED here at BofA. And I'm pleased to be joined by Mark -- Mike, who's the CMO of HUTCHMED. And I think Mike's going to give some prepared remarks to set the stage, and then we'll jump into Q&A. So over to you Mike.

Ming Shi;China;Limited;Executive VP
HUTCHMED;Head of R&D and Chief Medical Officer

()- -

Yes. Thank you, Alec. Yes, it's a great pleasure to be here. And I just want to have a few words about HUTCHMED, is a biotech company based -- headquartered in Hong Kong. It's been for 20 years, and we have three products already marketed in China, savolitinib, fruquintinib and surufatinib. And we also have a full integrated discovery, development and the commercial pipeline in China. In -- extra China side,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investorsā€™ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot